ImmunoPrecise Antibodies Ltd. is a technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. ImmunoPrecise Antibodies Ltd. is based in VICTORIA.
| Revenue (Most Recent Fiscal Year) | $18.16M |
| Net Income (Most Recent Fiscal Year) | $-20.13M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.51 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.01 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -211.85% |
| Net Margin (Trailing 12 Months) | -190.76% |
| Return on Equity (Trailing 12 Months) | -88.87% |
| Return on Assets (Trailing 12 Months) | -49.26% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.32 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.11 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.45 |
| Inventory Turnover (Trailing 12 Months) | 5.94 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.93 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.06 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.78 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.16 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 45.76M |
| Free Float | 42.64M |
| Market Capitalization | $26.28M |
| Average Volume (Last 20 Days) | 0.29M |
| Beta (Past 60 Months) | -0.05 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.83% |
| Percentage Held By Institutions (Latest 13F Reports) | 6.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |